Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBIT: 2019-2024

Historic EBIT for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$201.1 million.

  • Centessa Pharmaceuticals' EBIT fell 15.91% to -$53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 32.26%. This contributed to the annual value of -$201.1 million for FY2024, which is 17.38% down from last year.
  • According to the latest figures from FY2024, Centessa Pharmaceuticals' EBIT is -$201.1 million, which was down 17.38% from -$171.3 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' EBIT peaked at -$10.4 million during FY2020, and registered a low of -$374.1 million during FY2021.
  • For the 3-year period, Centessa Pharmaceuticals' EBIT averaged around -$194.9 million, with its median value being -$201.1 million (2024).
  • Per our database at Business Quant, Centessa Pharmaceuticals' EBIT slumped by 3,483.18% in 2021 and then surged by 43.26% in 2022.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' EBIT stood at -$10.4 million in 2020, then plummeted by 3,483.18% to -$374.1 million in 2021, then soared by 43.26% to -$212.3 million in 2022, then grew by 19.31% to -$171.3 million in 2023, then declined by 17.38% to -$201.1 million in 2024.